ArticleThe journal of allergy and clinical immunology. In practice2020
Trends and Disparities in Asthma Biologic Use in the United States.
Article in The journal of allergy and clinical immunology. In practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07396987 (Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation), which is not on this map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation
Who cites it
49 citing papers in PubMed.
- The Hidden Risk of Toxoplasmosis in the Expanding Immunomodulated Host Population: A Call for Guidelines and Registries in Patients on Biologics, Small Molecules, and Cellular Therapies.Pathogens (Basel, Switzerland) · 2026Article
- Population-Level Trends in Asthma Exacerbations After Introduction of Respiratory Biologics.JAMA network open · 2026Article
- Respiratory Biologics Utilization, Prescription Predictors, and Outcomes in Patients With Asthma and Comorbid Overweight or Obesity.The journal of allergy and clinical immunology. In practice · 2026Observational
- Article
- Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning.JAMA network open · 2026Article
- Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2026Article
- Primary care provider referral patterns and awareness of biologic therapy for uncontrolled asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Costs of Single Maintenance and Reliever Therapy vs Traditional Therapy for Asthma.JAMA network open · 2026Article
- Racial and Ethnic Disparities in the Use of Expensive Medications: A Focus on Sugammadex in the Pediatric Perioperative Setting.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Racial and Socioeconomic Differences in Real-World Use of Biologic Therapy for Asthma.Journal of asthma and allergy · 2026Article
- Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.Journal of asthma and allergy · 2026Article
- Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review.Current allergy and asthma reports · 2025Article
- Current practices, perceptions and future challenges in the management of moderate to severe COPD: a cross-sectional survey of respiratory consultants in the Republic of Ireland.BMJ open respiratory research · 2025Article
- Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization.American journal of rhinology & allergy · 2025Article
- Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions.The Journal of allergy and clinical immunology · 2025Article
- Real-World Biologic Use Patterns in Severe Asthma, 2015-2021: The CLEAR Study.Pragmatic and observational research · 2025Article
- Geographic and economic influences on benralizumab prescribing for severe asthma in Japan.Scientific reports · 2024Article
- Article
- Pharmacoequity in Allergy-Immunology: Disparities in Access to Medications for Allergic Diseases and Proposed Solutions in the United States and Globally.The journal of allergy and clinical immunology. In practice · 2024Review
- Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry.Journal of asthma and allergy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFrom 2003 to 2015, only 1 biologic was approved for the treatment of moderate to severe asthma in the United States. Since 2015, 4 new asthma biologics were approved by the US Food and Drug Administration.
objectiveTo describe trends and disparities of asthma biologic use in the United States from 2003 to 2018.
methodsWe conducted a retrospective analysis using a cohort developed from the OptumLabs Data Warehouse. Prevalent and incident asthma biologic users were identified, and characteristics of users and nonusers were analyzed using regression analysis. Clinician prescribing behavior was described.
resultsUse of biologic medications remains uncommon among individuals with asthma, with prevalence peaking in 2006 at 3 in 1000 individuals with asthma. Several factors are associated with a higher likelihood of asthma biologic use: middle age, higher income, commercial insurance, and access to a specialist. Most clinicians (65%) in the cohort prescribed only 1 biologic.
conclusionsWe report low overall use of asthma biologics and evidence of disparities in access to asthma biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.